Population Pharmacokinetic Analyses of Ertugliflozin in Select Ethnic Populations

Ertugliflozin, a sodium‐glucose cotransporter 2 inhibitor, is approved for treatment of type 2 diabetes. Two population pharmacokinetic (PK) analyses were conducted, using data from up to 17 phase 1 to 3 studies, to characterize ertugliflozin PK parameters in select ethnic subgroups: (1) East/Southe...

Descripción completa

Detalles Bibliográficos
Autores principales: Fediuk, Daryl J., Sahasrabudhe, Vaishali, Dawra, Vikas Kumar, Zhou, Susan, Sweeney, Kevin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291861/
https://www.ncbi.nlm.nih.gov/pubmed/34213819
http://dx.doi.org/10.1002/cpdd.970

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291861/
https://www.ncbi.nlm.nih.gov/pubmed/34213819
http://dx.doi.org/10.1002/cpdd.970

Ejemplares similares